CHILD VACCINE: Pfizer, BioNTech ask FDA to authorize vaccine for children 5 to 11

Vaccine maker Pfizer and its German partner, BioNTech, have asked the Food and Drug Administration to authorize their coronavirus vaccine for emergency use for children ages 5 to 11, the companies announced Thursday.

An estimated 28 million children in the United States would be eligible for the shots if regulators give the green light — a process expected to take several weeks. The vaccine would be the first one made available in this country for children younger than 12.

“With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against covid-19,” Pfizer said in a tweet. Pfizer-BioNTech submitted initial data to the FDA last month for a 10-microgram dose in children, smaller than what is given to older patients.

Share on:

Share on facebook
Share on twitter
Share on linkedin